These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20358262)

  • 21. Comparison of cohort and nested case-control designs for estimating the effect of time-varying drug exposure on the risk of adverse event in the presence of ties.
    Manitchoko L; Abrahamowicz M; Tubert-Bitter P; Benichou J; Thiébaut ACM
    Biom J; 2023 Aug; 65(6):e2100384. PubMed ID: 36846937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmacoepidemiolgy: regulatory basis, methodological approaches and scope].
    Ahid S; Belaguide K; Cherrah Y
    East Mediterr Health J; 2012 Jan; 18(1):85-93. PubMed ID: 22360016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluating bias from birth-cohort effects in the age-based cox proportional hazards model.
    Hein MJ; Schubauer-Berigan MK; Deddens JA
    Epidemiology; 2011 Mar; 22(2):249-56. PubMed ID: 21233713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Left truncation results in substantial bias of the relation between time-dependent exposures and adverse events.
    Hazelbag CM; Klungel OH; van Staa TP; de Boer A; Groenwold RH
    Ann Epidemiol; 2015 Aug; 25(8):590-6. PubMed ID: 25935711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A tutorial on the use of instrumental variables in pharmacoepidemiology.
    Ertefaie A; Small DS; Flory JH; Hennessy S
    Pharmacoepidemiol Drug Saf; 2017 Apr; 26(4):357-367. PubMed ID: 28239929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inflation of type I error rates due to differential misclassification in EHR-derived outcomes: Empirical illustration using breast cancer recurrence.
    Chen Y; Wang J; Chubak J; Hubbard RA
    Pharmacoepidemiol Drug Saf; 2019 Feb; 28(2):264-268. PubMed ID: 30375122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Time-related biases in pharmacoepidemiology.
    Suissa S; Dell'Aniello S
    Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1101-1110. PubMed ID: 32783283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Misclassification of exposure is high when interview data on drug use are used as a proxy measure of chronic drug use during follow-up.
    Beiderbeck AB; Sturkenboom MC; Coebergh JW; Leufkens HG; Stricker BH
    J Clin Epidemiol; 2004 Sep; 57(9):973-7. PubMed ID: 15504640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug exposure misclassification in pharmacoepidemiology: Sources and relative impact.
    Hempenius M; Groenwold RHH; de Boer A; Klungel OH; Gardarsdottir H
    Pharmacoepidemiol Drug Saf; 2021 Dec; 30(12):1703-1715. PubMed ID: 34396634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new likelihood model for analyses of pharmacoepidemiologic case-control studies which avoids decision rules for determining latent exposure status.
    Støvring H; Pottegård A; Hallas J
    BMC Med Res Methodol; 2021 Jul; 21(1):144. PubMed ID: 34238230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Limited impact of drug exposure misclassification from non-benefit thiazolidinedione drug use on mortality and hospitalizations from Saskatchewan, Canada: a cohort study.
    Gamble JM; Johnson JA; McAlister FA; Majumdar SR; Simpson SH; Eurich DT
    Clin Ther; 2015 Mar; 37(3):629-42. PubMed ID: 25596665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conditions for confounding of interactions.
    Liu A; Abrahamowicz M; Siemiatycki J
    Pharmacoepidemiol Drug Saf; 2016 Mar; 25(3):287-96. PubMed ID: 26676843
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Challenges and opportunities for pharmacoepidemiology in drug-therapy decision making.
    Etminan M; Gill S; Fitzgerald M; Samii A
    J Clin Pharmacol; 2006 Jan; 46(1):6-9. PubMed ID: 16397278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Using probability of drug use as independent variable in a register-based pharmacoepidemiological cause-effect study-An application of the reverse waiting time distribution.
    Hallas J; Pottegård A; Støvring H
    Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1520-1526. PubMed ID: 29024218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal matching ratios in drug safety surveillance.
    Wang SV; Schneeweiss S; Rassen JA
    Epidemiology; 2014 Sep; 25(5):772-3. PubMed ID: 25076153
    [No Abstract]   [Full Text] [Related]  

  • 36. When should case-only designs be used for safety monitoring of medical products?
    Maclure M; Fireman B; Nelson JC; Hua W; Shoaibi A; Paredes A; Madigan D
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():50-61. PubMed ID: 22262593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New use of prescription drugs prior to a cancer diagnosis.
    Pottegård A; Hallas J
    Pharmacoepidemiol Drug Saf; 2017 Feb; 26(2):223-227. PubMed ID: 27889931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immortal time bias in drug safety cohort studies: spontaneous abortion following nonsteroidal antiinflammatory drug exposure.
    Daniel S; Koren G; Lunenfeld E; Levy A
    Am J Obstet Gynecol; 2015 Mar; 212(3):307.e1-6. PubMed ID: 25265406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An empirical assessment of immeasurable time bias in the setting of nested case-control studies: Statins and all-cause mortality among patients with heart failure.
    Oh IS; Filion KB; Jeong HE; Shin JY
    Pharmacoepidemiol Drug Saf; 2019 Oct; 28(10):1318-1327. PubMed ID: 31432599
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between pacifier use and breast-feeding, sudden infant death syndrome, infection and dental malocclusion.
    Callaghan A; Kendall G; Lock C; Mahony A; Payne J; Verrier L
    JBI Libr Syst Rev; 2005; 3(6):1-33. PubMed ID: 27819973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.